Vancouver, British Columbia – The press wire – September 3, 2021 – BYND Cannasoft Enterprises Inc. (“BYND” or the “Company”) is pleased to announce that the process to register its common shares for trading on the Nasdaq Capital Market (the “Nasdaq List ”). In connection with the proposed Nasdaq listing, the Company has engaged a US legal advisor to provide advice on US securities law matters and to assist in the preparation and filing of a formal registration statement. 20-F with the United States Securities and Exchange Commission. The Company estimates that if successful, the Nasdaq listing process will take approximately 6 months. Readers are cautioned that the Company has not yet submitted its formal application for Nasdaq listing and that there is no guarantee that listing on Nasdaq will be approved.
In connection with the proposed listing on Nasdaq, the Company has negotiated a private placement financing with a single high net worth investor, AGROINVESTMENT SA which will see the Company issue 2 403 846 ordinary shares (the “BYND actions“) at an issue price of $ 1.04 per share as well as 400,000 non-transferable share purchase warrants (the”BYND Warrants“) to the investor in exchange for gross proceeds of $ 2,500,000 (the”Private placement“). Each BYND warrant will entitle the investor to acquire one (1) additional common share of BYND, at a price of $ 1.30 per share, for a period of two (2) years. All BYND shares, BYND warrants and all shares issuable upon exercise of BYND warrants will be subject to a four-month holding period calculated from the close of the private placement.
Pending completion of the Nasdaq listing, the Company has agreed to loan the $ 2,500,000 of the proceeds of the private placement to the investor (the “Investor loan“) and the investor has agreed to deposit the BYND Shares and BYND Warrants into receivership with Pershing LLC. as security for the Investor Loan. Upon successful completion of the Nasdaq listing, the full amount of the investor loan will become immediately due and repayable to the Company, without interest and if repaid at maturity, the BYND shares and the BYND warrants. will be delivered to the investor and the investor will acquire the right to nominate one (1) person for election to serve on the board of directors of BYND.
If the investor loan is not repaid at maturity or if the Nasdaq listing has not taken place by April 30, 2022, the escrow agent will return the BYND shares and the BYND warrants to BYND, for cancellation and the investor loan will be canceled.
Closing of the private placement and investor loan transaction is subject to a number of conditions to the benefit of each party, including applicable regulatory approvals and, in the case of BYND, approval by the board of directors. .
Mr. Yftah Ben Yaackov, CEO of BYND noted that “We realize the vision of the company. The ability to be listed on the Nasdaq Capital Market along with the latest funding will help us realize and accelerate the strategic plan to expand the Company’s business in Israel and abroad, while creating real value for our customers. shareholders”.
About BYND Cannasoft Enterprises Inc.
BYND is an integrated software / cannabis company, based in Israel.
BYND owns and markets a proprietary customer relationship management (CRM) software product known as “Benefit CRM”. BYND’s Benefit CRM software enables small and medium-sized businesses to optimize their day-to-day business activities such as sales management, personnel management, marketing, call center operations and asset management. BYND’s next-generation Benefit CRM platform is nearing completion and will soon be ready for BETA testing.
CRM on cannabis
Building on its 20 years of experience in CRM software, BYND recently began the development of an innovative new CRM platform, designed specifically to meet the needs of the medical cannabis industry. This new platform will be the first of its kind in the field of medical cannabis and the Company is confident that it will transform the industry into a more organized, accessible and price transparent market. The data and information collected during the operation of the cannabis farm (see below) and the products it manufactures will allow BYND to test its new Cannabis CRM platform and adjust the platform as necessary. . Additionally, operating the cannabis farm and selling medical cannabis will generate additional revenue to further support BYND in the early years of its cannabis CRM platform rollout.
BYND recently obtained a master cultivation license for the cultivation of medical cannabis in Israel and intends to build a 3.7-acre farm near Ashkelon Israel, to cultivate medical cannabis. The company’s plans include the construction of 4 state-of-the-art greenhouses, housing approximately 2.5 acres of total growing area. BYND estimates that once fully operational, its cannabis farm facility will be able to produce 7,500 kg of raw cannabis each year. BYND also intends to work with strategic partners to develop and market new, exclusive cannabis-infused products for sale throughout Israel and for export.
For more information please refer to the information available on the Company’s website: www.cannasoft-crm.com, the CSE website: www.thecse.com/en/listings/life-sciences/bynd-cann and on SEDAR: www.sedar.com.
Phone. : (604) 833-6820
E-mail: [email protected]
Caution regarding forward-looking statements
This press release contains forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from the statements made. When used in this document, the words “could”, “would”, “could”, “will”, “the intention”, “plan”, “anticipate”, “believe”, “estimate”, ” expect ”and similar phrases are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. There are many factors that could cause our actual results to differ materially from statements made, including factors discussed in documents we have filed with Canadian securities regulators. If one or more of these risks and uncertainties, such as currency and interest rate fluctuations, increased competition, and general economic and market factors, occur or if the assumptions underlying the forward-looking statements prove to be incorrect , actual results could differ materially from those described in this document as expected. , planned, anticipated or expected. We do not intend and assume no obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to place undue reliance on these forward-looking statements.
The CSE has not reviewed, approved or disapproved of the contents of this press release.